parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in mesothelial cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 205	0.79
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 7097

receipt 7105: VIPR2 in dopamine neurons, braak

power: full sample -0.33 (p 0.182, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.35 (p 0.153, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.48 (p 0.046, n 18). not the mix.
skeptic: leave-one-out range -0.48 to -0.24, sign flips 0; without severely affected donors -0.33 (p 0.182, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for VIPR2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7104: VIPR2 in oligodendrocytes, braak

power: full sample +0.01 (p 0.969, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.02 (p 0.949, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.23 (p 0.369, n 18). could be the mix.
skeptic: leave-one-out range -0.11 to +0.14, sign flips 8; without severely affected donors +0.01 (p 0.969, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for VIPR2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts